| Identification | Back Directory | [Name]
GSK2894631A | [CAS]
2101626-26-8 | [Synonyms]
GSK2894631A
HPGDS inhibitor 2
7-(Difluoromethoxy)- N-[trans-4-(1-hydroxy-1-methylethyl)cyclohexyl]-3-quinolinecarboxamide
3-Quinolinecarboxamide, 7-(difluoromethoxy)-N-[trans-4-(1-hydroxy-1-methylethyl)cyclohexyl]- | [Molecular Formula]
C20H24F2N2O3 | [MOL File]
2101626-26-8.mol | [Molecular Weight]
378.41 |
| Chemical Properties | Back Directory | [Boiling point ]
572.5±45.0 °C(Predicted) | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, away from moisture and light | [solubility ]
DMSO:150.0(Max Conc. mg/mL);396.39(Max Conc. mM) | [form ]
Solid | [pka]
13.22±0.40(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
HPGDS inhibitor 2 is a highly potent and selective hematopoietic prostaglandin D synthase (H-PGDS) inhibitor with an IC50 of 9.9 nM[1]. | [References]
[1] Deaton DN, et al. The discovery of quinoline-3-carboxamides as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors. Bioorg Med Chem. 2019 Apr 15;27(8):1456-1478. DOI:10.1016/j.bmc.2019.02.017 |
|
|